Oral bisphosphonates and colon cancer: an update

Eiken, Pia; Vestergaard, Peter

doi:10.1177/1759720x15582144

Cited by 7 publications

(7 citation statements)

References 40 publications

(197 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be the case not only for inflammatory conditions such as irritable bowel syndrome or inflammatory bowel disease but also for colorectal cancer. In fact, animal studies as well as preliminary clinical evidence suggest that bisphosphonates may be a treatment modality worth further exploration for these conditions (Ballester et al, 2007;Eiken & Vestergaard, 2015;Pazianas & Russell, 2012 Anti-angiogenic effects have been described for bisphosphonates (Hasmim, Bieler, & Rüegg, 2007;Wood et al, 2002), and this mechanism has also been implicated in their anti-tumorigenic effects (Reusser et al, 2014;Van Acker, Anguille, Willemen, Smits, & Van Tendeloo, 2016), which in turn may be a factor in reducing bone cancer-related pain. An anti-angiogenic effect has been hypothesized…”

Section: Anti-inflammatory Effectsmentioning

confidence: 99%

Pharmacology of bisphosphonates in pain

Tzschentke

2019

British J Pharmacology

View full text Add to dashboard Cite

show abstract

Section: Anti-inflammatory Effectsmentioning

confidence: 99%

Pharmacology of bisphosphonates in pain

Tzschentke

2019

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…However, in one of the CPRD studies, the association estimates were similar for men (hazard ratio [HR] 0.78; 95% CI: 0.47, 1.28) and women (HR 0.74; 95% CI: 0.56, 0.97) 9 . It has been suggested that bisphosphonate users may be a more health conscious group 20 , which may be particularly pronounced among men and may explain our stronger findings.…”

Section: Discussionmentioning

confidence: 63%

“…Three of these studies included overlapping populations from the Clinical Practice Research Datalink (CPRD; previously known as the General Practice Research Database)479, and the most recent study7 had the lowest percentage of missing BMI data and found a weakly positive association (OR 1.10; 95% CI: 1.00, 1.22) between bisphosphonate use and colorectal cancer specifically within the CPRD7. This suggests that the inverse association may be due to residual confounding by BMI20. We similarly found no significant association between oral bisphosphonates and colorectal cancer after adjustment for BMI, although a large proportion of participants were missing BMI data and the association between oral bisphosphonates and colorectal cancer was weaker within the population that had BMI data.…”

Section: Discussionmentioning

confidence: 99%

“…With the exception of the earliest meta-analysis 14 , the resulting meta-analyses have concluded that oral bisphosphonates are associated with a decreased risk of colorectal cancer 15 16 17 18 19 . However, a recent review of observational studies and meta-analyses considering the association of oral bisphosphonates and colorectal cancer suggested that residual confounding may explain the detected inverse associations 20 . Additionally, only a few studies 5 6 10 considered site-specific associations.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Oral bisphosphonates and colorectal cancer

Vogtmann

Corley

Almers

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Use of oral bisphosphonates has been associated with a decreased risk of colorectal cancer (CRC), but the association may be related to residual confounding by healthy lifestyle or body mass index (BMI). Therefore, we conducted a prospective nested case-control study within the Kaiser Permanente, Northern California health system cohort. In total, 12,505 CRC cases were individually matched to 599,534 controls. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using conditional logistic regression models with adjustment for important covariates extracted from the database. Participants who had ever used oral bisphosphonates were less likely than non-users to be diagnosed with CRC (OR 0.82; 95% CI: 0.74, 0.89). Colon and rectum site-specific associations were similar to the overall association. A stronger inverse association for ever use of bisphosphonates was observed for men (OR 0.63; 95% CI: 0.47, 0.85), however when stratified by previous lower endoscopy, the association was only observed in the participants who did not have a previous lower endoscopy (OR 0.73 (0.64, 0.83)). In conclusion, we found that oral bisphosphonate use was associated with a decreased odds of CRC, however this association may be due to residual confounding by BMI or another confounder.

show abstract

“…In addition, observational studies and meta-analyses have associated osteoporosis drugs with unchanged or decreased colorectal cancer risk. 31 – 33 Regarding other non-GU cancers, McGlynn et al reported that female patients with osteoporosis had a significantly higher risk of liver cancer and hematologic malignancy compared with female patients without osteoporosis. 28 The women with SCI in the current study also exhibited a significantly higher risk of liver cancer and hematologic malignancy than women without SCI.…”

Section: Discussionmentioning

confidence: 99%

Risk of Nongenitourinary Cancers in Patients With Spinal Cord Injury

et al. 2016

View full text Add to dashboard Cite

Little information is available regarding the risk of nongenitourinary (GU) cancers in patients with spinal cord injury (SCI). The authors conducted a nationwide population-based study to investigate whether a higher risk of non-GU cancer is seen among patients with SCI.Data retrieved from the National Health Insurance Research Database of Taiwan were used in this study. A total of 41,900 patients diagnosed with SCI between 2000 and 2011 were identified from the National Health Insurance Research Database and comprised the SCI cohort. Each of these patients was randomly frequency matched with 4 people from the general population (without SCI) according to age, sex, comorbidities, and index year. Cox proportional hazards regression analysis was used to calculate adjusted hazard ratios and 95% confidence intervals and determine how SCI affected non-GU cancer risk.No significant difference in overall non-GU cancer risk was observed between the SCI and control groups. The patients with SCI exhibited a significantly higher risk of developing esophageal, liver, and hematologic malignancies compared with those without SCI. By contrast, the SCI cohort had a significantly lower risk of colorectal cancer compared with the non-SCI cohort (adjusted hazard ratio = 0.80, 95% confidence interval = 0.69–0.93). Additional stratified analyses by sex, age, and follow-up duration revealed various correlations between SCI and non-GU cancer risk.The patients with SCI exhibited higher risk of esophageal, liver, and hematologic malignancies but a lower risk of colorectal cancer compared with those without SCI. The diverse patterns of cancer risk among the patients with SCI may be related to the complications of chronic SCI.

show abstract

Oral bisphosphonates and colon cancer: an update

Cited by 7 publications

References 40 publications

Pharmacology of bisphosphonates in pain

Pharmacology of bisphosphonates in pain

Oral bisphosphonates and colorectal cancer

Risk of Nongenitourinary Cancers in Patients With Spinal Cord Injury

Contact Info

Product

Resources

About